Success Stories

The National Cancer Institute’s Technology Transfer Center (TTC) facilitates partnerships between the NIH research laboratories and external partners. With a specialized team, TTC guides the interactions of our partners from the point of discovery, to patenting, through invention development to licensing.

We play a key role in helping to accelerate  development of cutting-edge research by connecting our partners to NIH’s world-class facilities, resources, and discoveries. Some of our partnerships have resulted in the commercialization of therapeutics, vaccines, diagnostics, medical devices and research tools that benefit patients worldwide. TTC is proud to share a few examples of our successful partnerships.

  • Dr. Steven Rosenberg and a colleague in the lab at the NCI Surgery Branch

    Partnership Resulting in Commercialization of Axicabtagene Ciloleucel

    In a new video produced by the Federal Laboratory Consortium, learn about the successful technology transfer of Axicabtagene ciloleucel, a highly personalized immunotherapy conceived by Dr. Steven Rosenberg of the NCI.

  • Dr. James Gulley, Co-Director for Immuno-Oncology, Clinical Director, NCI

    Success story: A New Immunotherapy Treatment for Merkel Cell Carcinoma

    Produced by the Federal Laboratory Consortium (FLC) for their Labs in Action series, "A New Immunotherapy Treatment for Merkel Cell Carcinoma" tells the story of the discovery, collaborative development and realization of a new treatment for a rare type of skin cancer.

  • Unituxin Image Reduced Size 17 5 MG

    Dinutuximab (Unituxin™) - A Success Story

    Learn about the 2015 FDA approval of Unituxin™ as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a rare cancer that most often occurs in young children, and the role that the NCI Technology Transfer Center played to facilitate this outcome.

  • HALAVEN Is A Prescription Medicine Used To Treat Adults With Breast Cancer That Has Spread To Other Parts of The Body

    Halaven - A Success Story

    Learn more about the technology transfer story behind the development of the drug, Halaven®.

  • Velcade For Injection 3.5

    Velcade - A Success Story

    The discovery of Velcade® for the treatment of multiple myeloma (MM) originated from a collaboration with ProScript Inc. and NCI scientists in the Developmental Therapeutics Program.

  • Inventor Kris Ylaya Reviewing Prototype

    Micatu Tissue Arrayer - A Success Story

    An NCI researcher recognized a critical need to create a low-cost, easy-to-use tissue microarrayer (TMA), an instrument used by researchers and pathologists to accurately examine tissue samples from patients.

  • Gardasil Injection

    Gardasil and Cervarix - A Success Story

    Learn the discovery to commercialization story for Gardasil, a vaccine to prevent human papillomavirus (HPV) infection, the primary cause of cervical cancer.

  • Bottle of Taxol for injection

    Taxol - A Success Story

    In the 1980s, the drug Taxol was fully developed under an agreement between NCI and Bristol-Myers Squibb.